Bioqual (OTCMKTS:BIOQ - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($1.36) earnings per share for the quarter, Zacks reports. Bioqual had a negative return on equity of 2.87% and a negative net margin of 1.99%.
Bioqual Trading Down 3.8 %
BIOQ stock traded down $2.50 on Tuesday, hitting $62.50. The company's stock had a trading volume of 250 shares, compared to its average volume of 225. The firm has a 50 day moving average of $66.46 and a two-hundred day moving average of $68.45. Bioqual has a 1 year low of $62.50 and a 1 year high of $80.00. The stock has a market cap of $55.63 million, a price-to-earnings ratio of -50.81 and a beta of -0.33.
Bioqual Company Profile
(
Get Free Report)
Bioqual, Inc provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer.
Featured Stories
Before you consider Bioqual, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioqual wasn't on the list.
While Bioqual currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
